Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 274,297 shares of the business's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $19.52, for a total transaction of $5,354,277.44. Following the transaction, the director owned 13,148 shares in the company, valued at $256,648.96. The trade was a 95.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dyne Therapeutics Stock Performance
DYN opened at $19.67 on Thursday. The firm has a market capitalization of $3.25 billion, a PE ratio of -5.56 and a beta of 1.29. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The firm's 50-day moving average price is $17.58 and its 200 day moving average price is $18.36. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.02). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Chardan Capital restated a "buy" rating and set a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. HC Wainwright decreased their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 3rd. Wall Street Zen lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, December 28th. JPMorgan Chase & Co. decreased their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating on the stock in a report on Tuesday, January 20th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Monday. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $35.14.
Check Out Our Latest Report on Dyne Therapeutics
Hedge Funds Weigh In On Dyne Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of DYN. T. Rowe Price Investment Management Inc. boosted its holdings in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock valued at $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. Orbis Allan Gray Ltd purchased a new stake in shares of Dyne Therapeutics in the 4th quarter valued at approximately $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $30,378,000. Perceptive Advisors LLC raised its stake in shares of Dyne Therapeutics by 543.7% in the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company's stock valued at $68,048,000 after acquiring an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Dyne Therapeutics by 572.9% in the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company's stock valued at $38,119,000 after acquiring an additional 2,565,570 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
